Iris L. A. Bodewes

Systemic interferon type I and type II signatures in primary Sjögren’s syndrome reveal differences in biological disease activity

Iris L. A. Bodewes, Shereen Al-Ali, Cornelia G van Helden-Meeuwsen et al. · Lara D. Veeken · 2018 · 120 citations · Full text

Life Sciences, Immunology, Autoimmunity +16

Innate immunity and interferons in the pathogenesis of Sjögren’s syndrome

Iris L. A. Bodewes, Albin Björk, Marjan A. Versnel et al. · Lara D. Veeken · 2018 · 80 citations

Life Sciences, Immunology, Pathobiology +17

Type I IFN signature in childhood-onset systemic lupus erythematosus: a conspiracy of DNA- and RNA-sensing receptors?

M. J. Wahadat, Iris L. A. Bodewes, Naomi I. Maria et al. · Arthritis Research & Therapy · 2018 · 77 citations · Full text

Life Sciences, Immunology, Molecular Biology +17

Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial

Iris L. A. Bodewes, Jacques‐Eric Gottenberg, Cornelia G van Helden-Meeuwsen et al. · Lara D. Veeken · 2019 · 72 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis

Iris L. A. Bodewes, Erika Huijser, Cornelia G van Helden-Meeuwsen et al. · Journal of Autoimmunity · 2018 · 67 citations · Full text

Medicine, Immunology, Molecular Medicine +13